CAPR Capricor Therapeutics, Inc.
Stable Earnings Power
F 30.0 / 100 pillar composite

AlphaQuality composite grade, weighted for stable earnings power businesses.

⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.

Grade overrides the 30.0 pillar composite — hard gates always win.

Profitability

Weight: 20%
D- 30
  • 5yr Avg ROIC -10.9%
  • Operating Margin Trend +2614.45 pp/yr

Capital Efficiency

Weight: 15%
F 0
  • 5yr Avg ROE -14.2%
  • 5yr Share-Count CAGR 19.1%

Growth Quality

Weight: 15%
C+ 60
  • 5yr Revenue CAGR 349.7%
  • 5yr EPS CAGR 0.0%
  • Revenue-Growth Years (5) 2/5

Cash Generation

Weight: 15%
F 0
  • 5yr FCF Margin -1896.9%
  • 5yr FCF/NI Conversion 0.00x

Balance Sheet

Weight: 20%
F 25
  • Net Debt / EBITDA 10.00x
  • Interest Coverage (EBIT/Int) -35.51x
  • Altman Z-Score 14.91

Stability

Weight: 15%
B- 67
  • EPS Volatility (σ/μ) 0.00
  • Piotroski F-Score 2
  • Negative-Revenue Years (5) 2/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Holding

2 of 2 gurus held; 1 added.

Holders
2
Avg Δ position
+718.9%
New buys
0
Full exits
0
  • Wood increased +1438%
As of Q1 2026